European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)

INCLUSION CRITERIA * Patients will be four years and older * Patients will have an established diagnosis of Lennox-Gastaut syndrome, and: * Documented history or current presence of multiple seizure types associated with LGS (including tonic or atonic seizures (drop attacks) and atypical absences) * Documented history or current presence of typical EEG abnormalities (e.g., bursts of slow spike and wave activity) * Presence of intellectual / learning disability (a variable degree is permitted) * Patients entered on the registry will be those requiring a modification in their current anti-epileptic medication. This includes but is not limited to patients who are commenced on rufinamide as adjuvant therapy EXCLUSION CRITERIA * Female patients who are pregnant, lactating, or whom are planning to become pregnant * Female patients, of child bearing potential, who are not willing to use appropriate contraception (This is at the discretion of the investigator) * Those starting rufinamide and for whom the investigator considers it necessary to administer in contradiction to the indications, and warnings within the current Summary of Product Characteristics (SPC).